EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

ROLE OF REMDISIVIR IN MODERATE AND SEVERE COVID PNEUMONIA PATIENTS IN PAKISTANI POPULATION

Dr. Shazia Awan, Dr. Aisha Ashfaq, Dr. Uzma Batool, Dr. Asifa Karamat, Dr. Khalid Shahzad*, Dr. Anum Ashfaq, Dr. Osama Niazi, Dr. Hayida Ali, Dr. Hina Ali and Dr. Irshad Khan

ABSTRACT

Background: Remdesivir is a broad spectrum nucleotide analogue that inhibits RNA-dependent RNA polymerase activity among a diverse group of RNA viruses. Non-clinical and clinical data suggest that remdesivir may be useful for the treatment of COVID-19. Objectives: To evaluate outcome of remdesivir administration among patients with moderate and severe COVID pneumonia. METHODS: Study Design: Cross sectional Prospective study. Study Setting: Pakistan atomic energy commission hospital, Chashma. Study Duration: 06 months. Data collection and analysis: 207 subjects aged 12 years and above of either gender who had SARS-CoV-2 infection confirmed by polymerase-chain-reaction assay or through radiographic evidence and either had oxygen saturation of >94% or less while they were breathing ambient air or were receiving supplemental oxygen with moderate and severe COVID pneumonia admitted in hospital for routine care were included in the study through a non probability / consecutive sampling. The primary endpoint was final outcome of the treatment and time to clinical recovery. Data was entered and analysed in SPSS ver: 21.0. Frequencies and percentages were calculated for qualitative variables and mean and standard deviation for quantitative variables. Outcome was cross tabulated for independent variables and t –test was used for numerical variables and chi-square test was used for nominal variables with p < .05 as statistical significant. Results: 207 subjects included in the study among them 62.8% were male and 37.2% were females. Mean age of patients was 50.9 + 13.796 years and mean duration of illness was 6.376 days with 1 – 12 days range. 96.6% of patient improved and 3.4% had deterioration in their condition. Outcome was cross tabulated with disease severity. 95.5% who had improved outcome was having moderate disease as compared to 93.1% who had severe disease as was statistically significant. (p < .038). Conclusion: The timely administration of remdesivir to moderate and severe COVID pneumonia patients can significantly reduce their mortality and morbidity and thus improve the outcome of the disease.

Keywords: COVID-19, Pneumonia, Remdesivir.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 February 2023 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: FEBRUARY ISSUE PUBLISHED

    FEBRUARY issue has been successfully launched on 1 FEBRUARY 2023.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database